New unemployment filings in Maryland fell significantly last week, offering a spot of positive news for the state's labor market as national claims also edged lower.
Investor Kevin O'Leary argues that rigid return-to-office policies are a competitive disadvantage, pushing high performers toward flexible employers and leaving companies with a diminished talent pool.
Air Products and Chemicals reported a 10% rise in adjusted EPS for its fiscal first quarter, driven by strategic pricing and productivity gains. While management affirmed full-year guidance, they highlighted persistent challenges in the helium market and a cautious approach to major clean energy investments.
The automotive safety giant posted historic sales and cash flow in 2025, powered by explosive growth with Chinese automakers and in India. While navigating a softer production forecast and tariff headwinds, management projects margin expansion for 2026.
Oxford Lane Capital (OXLC) reported a challenging third fiscal quarter, marked by a significant drop in net asset value and investment income, prompting management to reduce its monthly distribution. The firm cited volatile conditions in the CLO and leveraged loan markets as key headwinds, while outlining a strategy to preserve capital for opportunistic investments.
Financial Institutions (FISI) reported solid Q4 and full-year 2025 results, beating guidance on key profitability metrics. Management highlighted disciplined loan growth, a strengthened capital position, and strategic shifts, while pointing to long-term opportunities from major industrial investments in its Upstate New York footprint.
The trading platform's launch of commission-free event contracts for the Big Game has sparked interest, but its shares continue to struggle, raising questions about its valuation and growth narrative.
United Natural Foods, Inc. launches a landmark grant program across all 50 U.S. states and Canada to celebrate its 50th year, even as its stock performance presents a mixed picture for value-focused investors.
A revised price target for Invesco Mortgage Capital (IVR) is prompting investors to reassess the mortgage REIT's trajectory amid evolving interest rate expectations and housing market dynamics.
Accent Group's strategic partnership with UK retail giant Frasers, including a planned rollout of Sports Direct stores in Australia, is drawing investor focus as it promises to reshape the footwear retailer's earnings profile. The move comes amid volatile share price performance, raising questions about the company's current valuation.
The global professional services firm reported 6% organic revenue growth for the second consecutive year, fueled by its Aon United strategy and strategic acquisitions like NFP. With $7 billion in available capital, Aon is poised to accelerate investments in high-growth areas, notably the burgeoning data center and alternative capital markets.
Saks Global moves to close over 60 Off 5th locations as part of Chapter 11 proceedings, signaling a strategic retreat from the competitive off-price segment to focus on core luxury brands.
While mortgage rates have inched up slightly this week, homebuyers are still facing significantly lower borrowing costs compared to last year's peak. We break down the monthly and long-term savings on a typical home purchase.
Goldman Sachs raises its price target for Zeta Global (ZETA), citing strategic positioning ahead of an expected surge in software sector mergers and acquisitions driven by valuation gaps and synergy potential.
Rosenblatt Securities initiates coverage on Credo Technology with a Neutral rating and a $170 price target, highlighting its strong position in high-speed connectivity for AI infrastructure while flagging competitive pressures. The note follows a more bullish target hike from Barclays earlier in the month.
Analyst firm Piper Sandler reiterates its Overweight rating on AGNC Investment Corp., highlighting a favorable shift in agency mortgage-backed securities spreads that could bolster the REIT's book value.
LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.
Investment firm TD Cowen has increased its price target on Tesla (TSLA) to $519, maintaining a Buy rating. The adjustment follows a fourth-quarter performance marked by strong margins and progress on autonomous driving projects, though tempered by higher capital expenditure forecasts and vague timelines for full self-driving technology.
Analysts at TD Cowen have increased their price target on logistics giant C.H. Robinson to $194, citing better-than-expected fourth-quarter results and margin resilience in a tough spot market, while maintaining a Hold rating.
Analyst Jason Seidl lowered CP's target to C$112 from C$116, citing reasonable valuation post-KCS merger but noting headwinds from negative estimate revisions and investor capital flowing toward U.S. rail M&A opportunities.
